Hofseth BioCare ASA (OSL:HBC)
Norway
· Delayed Price · Currency is NOK 1.295
-0.045 (-3.36%)
At close: Mar 6, 2026
Hofseth BioCare ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 254.43 | 256.83 | 190.82 | 119.13 | 76.88 | Upgrade
|
| Other Revenue | 1.91 | 8.71 | 27.7 | 1.32 | 10.74 | Upgrade
|
| Revenue | 256.34 | 265.54 | 218.51 | 120.45 | 87.62 | Upgrade
|
| Revenue Growth (YoY) | -3.46% | 21.52% | 81.42% | 37.47% | 26.52% | Upgrade
|
| Cost of Revenue | 160.97 | 189.81 | 165 | 102.49 | 77.05 | Upgrade
|
| Gross Profit | 95.37 | 75.73 | 53.51 | 17.96 | 10.57 | Upgrade
|
| Selling, General & Admin | 81.7 | 91.37 | 76.25 | 76.03 | 60.35 | Upgrade
|
| Other Operating Expenses | 86.61 | 49.66 | 43.38 | 40.13 | 39.43 | Upgrade
|
| Operating Expenses | 207.72 | 180.81 | 156.04 | 146.39 | 129.13 | Upgrade
|
| Operating Income | -112.35 | -105.08 | -102.53 | -128.43 | -118.56 | Upgrade
|
| Interest Expense | -22.83 | -15.69 | -7.54 | -9.95 | -9.39 | Upgrade
|
| Interest & Investment Income | 2 | 0.79 | 0.55 | 0.65 | 0.61 | Upgrade
|
| Earnings From Equity Investments | 2.15 | -7.48 | 2.54 | -0.2 | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | -3.68 | 2.16 | 0.3 | 0.74 | 0.91 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0 | - | -0.06 | Upgrade
|
| EBT Excluding Unusual Items | -134.71 | -125.3 | -106.69 | -137.2 | -126.46 | Upgrade
|
| Asset Writedown | - | - | - | -0.19 | - | Upgrade
|
| Pretax Income | -134.71 | -125.3 | -106.69 | -137.39 | -126.46 | Upgrade
|
| Income Tax Expense | 0.18 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -134.88 | -125.3 | -106.69 | -137.39 | -126.46 | Upgrade
|
| Minority Interest in Earnings | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Net Income | -134.88 | -125.3 | -106.68 | -137.39 | -126.46 | Upgrade
|
| Net Income to Common | -134.88 | -125.3 | -106.68 | -137.39 | -126.46 | Upgrade
|
| Shares Outstanding (Basic) | 411 | 411 | 395 | 375 | 358 | Upgrade
|
| Shares Outstanding (Diluted) | 411 | 411 | 395 | 375 | 358 | Upgrade
|
| Shares Change (YoY) | 0.04% | 4.01% | 5.43% | 4.72% | 7.25% | Upgrade
|
| EPS (Basic) | -0.33 | -0.30 | -0.27 | -0.37 | -0.35 | Upgrade
|
| EPS (Diluted) | -0.33 | -0.30 | -0.27 | -0.37 | -0.35 | Upgrade
|
| Free Cash Flow | -40.92 | -12.22 | -5.43 | -49.19 | -84.7 | Upgrade
|
| Free Cash Flow Per Share | -0.10 | -0.03 | -0.01 | -0.13 | -0.24 | Upgrade
|
| Gross Margin | 37.21% | 28.52% | 24.49% | 14.91% | 12.06% | Upgrade
|
| Operating Margin | -43.83% | -39.57% | -46.92% | -106.63% | -135.32% | Upgrade
|
| Profit Margin | -52.62% | -47.19% | -48.82% | -114.06% | -144.34% | Upgrade
|
| Free Cash Flow Margin | -15.96% | -4.60% | -2.49% | -40.84% | -96.67% | Upgrade
|
| EBITDA | -72.93 | -90.71 | -89.83 | -118.46 | -104.57 | Upgrade
|
| EBITDA Margin | -28.45% | -34.16% | -41.11% | -98.35% | -119.35% | Upgrade
|
| D&A For EBITDA | 39.41 | 14.37 | 12.7 | 9.97 | 14 | Upgrade
|
| EBIT | -112.35 | -105.08 | -102.53 | -128.43 | -118.56 | Upgrade
|
| EBIT Margin | -43.83% | -39.57% | -46.92% | -106.63% | -135.32% | Upgrade
|
| Revenue as Reported | 256.34 | 265.54 | 218.51 | 120.45 | 87.62 | Upgrade
|
| Advertising Expenses | - | 15.33 | 13.49 | 15.04 | 13.03 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.